Form 4: Crescent Biopharma CFO Awarded Significant Equity

Crescent Biopharma's Chief Financial Officer, Richard William Scalzo, received significant equity awards including Restricted Stock Units and stock options.

Summary

• Richard William Scalzo, Chief Financial Officer of Crescent Biopharma, Inc. (CBIO), was granted equity awards on December 15, 2025.
• The awards include 19,422 Ordinary Shares in the form of Restricted Stock Units (RSUs).
• These RSUs will vest in approximately equal three-month installments over four years, starting from December 15, 2025, contingent on continuous employment.
• An additional 57,688 Stock Options (right to buy) were granted with an exercise price of $13.21 per share.
• These stock options will vest with respect to 1/48th of the option on each monthly anniversary of December 15, 2025, also contingent on continuous employment, and have an expiration date of December 15, 2035.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation that aligns management's interests with shareholders, which is generally viewed positively for corporate governance and long-term performance incentives.

Positives

• The equity awards align the Chief Financial Officer's long-term financial interests with those of the shareholders, incentivizing sustained performance.
• The vesting schedules for both RSUs and stock options promote executive retention over a multi-year period.

Negatives

• The issuance of new shares upon RSU vesting and option exercise could lead to minor dilution for existing shareholders over time.

Risks

• The vesting of both Restricted Stock Units and stock options is contingent upon Richard William Scalzo remaining continuously employed by or providing services to Crescent Biopharma, Inc. or its subsidiaries through each vesting date.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the Chief Financial Officer to the company's performance and strategic objectives, aligning future incentives with shareholder value creation.

Industry Context

The granting of equity awards, such as Restricted Stock Units and stock options, to key executives is a standard practice within the biopharmaceutical industry. This compensation structure is widely used to attract, retain, and motivate top talent, aligning their performance incentives with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• The use of a combination of Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules is a common and well-established executive compensation strategy across publicly traded companies, particularly prevalent in growth-oriented sectors like biotechnology.
• This approach is consistent with global benchmarks for executive incentive plans, aiming to foster long-term commitment and align management's interests with shareholder returns.
• While specific comparable companies or projects are not detailed in this Form 4, the structure of these awards is typical for a company of Crescent Biopharma's profile in the biotech sector.

Corporate Governance

Related Party Transactions

• The equity awards granted to Richard William Scalzo, the Chief Financial Officer, constitute a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting/exercise, but also benefit from increased alignment of management's interests with long-term company performance.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.
• Management: Provides significant long-term incentives and retention mechanisms for the Chief Financial Officer.

Next Steps

• Richard William Scalzo's continued employment with Crescent Biopharma, Inc. or its subsidiaries is required for the vesting of the Restricted Stock Units and stock options over their respective schedules.

Key Dates

Keywords

Crescent Biopharma, CBIO, Richard William Scalzo, Chief Financial Officer, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Award, Executive Compensation, Insider Transaction, Form 4, Biopharma